why choose us

First received: July 18, 2022

Clinical Trial: Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: High Grade Astrocytic Tumor

Study Type: INTERVENTIONAL


Official Title: Efficacy and Safety Study of Neoadjuvant Efineptakin Alfa (NT-I7) and Pembrolizumab in Recurrent Glioblastoma

Brief Summary: This phase II trial tests the safety and side effects of efineptakin alfa and pembrolizumab in treating patients with glioblastoma that has come back (recurrent).Efineptakin alfa is an immunotherapy drug that works by helping the immune system fight tumor cells.Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.Giving efineptakin alfa and pembrolizumab may kill more tumor…

Read more